NASDAQ:SHPG - Shire Stock Price, Price Target & More

Get Started

$169.89 +0.94 (+0.56 %)

(As of 05/22/2018 04:00 PM ET)

Previous Close$169.89

Today's Range$169.69 - $170.89

52-Week Range$123.73 - $187.58

Volume966,253 shs

Average Volume1.52 million shs

Market Capitalization$51.55 billion

P/E Ratio11.21

Dividend Yield0.62%

Beta1.3

About Shire (NASDAQ:SHPG)

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.

Receive SHPG News and Ratings via Email

Sign-up to receive the latest news and ratings for SHPG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:SHPG

CUSIPN/A

Webwww.shire.com

Phone353-1609-6000

Debt

Debt-to-Equity Ratio0.45

Current Ratio1.14

Quick Ratio0.66

Price-To-Earnings

Trailing P/E Ratio11.21

Forward P/E Ratio11.13

P/E Growth1.34

Sales & Book Value

Annual Sales$15.16 billion

Price / Sales3.41

Cash Flow$22.7430 per share

Price / Cash7.47

Book Value$119.43 per share

Price / Book1.42

Profitability

EPS (Most Recent Fiscal Year)$15.15

Net Income$4.27 billion

Net Margins28.96%

Return on Equity13.60%

Return on Assets6.92%

Miscellaneous

Employees23,044

Outstanding Shares303,950,000

Shire (NASDAQ:SHPG) Frequently Asked Questions

What is Shire's stock symbol?

Shire trades on the NASDAQ under the ticker symbol "SHPG."

How often does Shire pay dividends? What is the dividend yield for Shire?

Shire announced a semiannual dividend on Friday, February 16th. Stockholders of record on Friday, March 9th will be given a dividend of $0.8937 per share on Tuesday, April 24th. This represents a dividend yield of 1.33%. The ex-dividend date of this dividend is Thursday, March 8th. This is a boost from Shire's previous semiannual dividend of $0.15. View Shire's Dividend History.

How were Shire's earnings last quarter?

Shire (NASDAQ:SHPG) issued its quarterly earnings data on Thursday, April, 26th. The biopharmaceutical company reported $3.86 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $3.58 by $0.28. The biopharmaceutical company had revenue of $3.77 billion for the quarter. Shire had a return on equity of 13.60% and a net margin of 28.96%. The business's quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.63 EPS. View Shire's Earnings History.

When is Shire's next earnings date?

Shire is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Shire.

What guidance has Shire issued on next quarter's earnings?

Shire issued an update on its FY18 earnings guidance on Thursday, April, 26th. The company provided EPS guidance of $14.90-15.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $15.23. The company issued revenue guidance of $15.4-15.9 billion, compared to the consensus revenue estimate of $15.48 billion.

What price target have analysts set for SHPG?

17 brokers have issued 12 month price objectives for Shire's shares. Their predictions range from $150.00 to $245.00. On average, they expect Shire's stock price to reach $201.6429 in the next twelve months. View Analyst Ratings for Shire.

What are Wall Street analysts saying about Shire stock?

Here are some recent quotes from research analysts about Shire stock:

1. According to Zacks Investment Research, "Sales of Shire’s Mydayis showed promise in the first six months of launch. Also, strong performance of Vyvanse, Cinryze and Elaprase continue to drive its top line. The label expansion of Firazyr in pediatrics and approval of Lyophilized Oncaspar in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology portfolio. Though the adult ADHD space is one of the largest and fastest growing segments of the market, it is highly genericized. Supply shortage for Cinryze and generic competition for Lialda had an unfavorable impact on the top line. Moreover, its shares have underperformed the industry in the past year. Estimates movement remains mixed ahead of the Q1 earnings results. The company has a positive record of earnings surprises in recent quarters." (4/23/2018)
2. Cantor Fitzgerald analysts commented, "Though it has not been confirmed by Shire yet, headlines from Reuters are reporting that Takeda (Not Covered) has made a takeover offer to Shire worth ~46.50 pounds/share (~$198 per ADS), which we estimate translates to ~ $61B (see Exhibit 1 on page 3 for details). Based on our conversations with shareholders, this seems like a reasonable starting price for a negotiation, but we think people will want to see $200+ unless it’s all cash." (4/16/2018)
3. Royal Bank of Canada analysts commented, "We don’t have a clue on the contribution of PhotonBlade in the qtr. FY18 guidance will be critical. Consensus currently is ~$52M. A number below consensus will be parsed almost immediately as to implied PhotonBlade / non- PhotonBlade growth." (2/5/2018)

Are investors shorting Shire?

Shire saw a increase in short interest in the month of April. As of April 30th, there was short interest totalling 1,486,913 shares, an increase of 110.7% from the April 13th total of 705,730 shares. Based on an average daily volume of 2,705,597 shares, the short-interest ratio is presently 0.5 days. Currently, 0.5% of the shares of the stock are short sold.

Who are some of Shire's key competitors?

Some companies that are related to Shire include Novartis (NVS), AbbVie (ABBV), Merck & Co. (MRK), Novo Nordisk (NVO), Abbott Laboratories (ABT), Bayer (BAYRY), GlaxoSmithKline (GSK), Sanofi (SNY), AstraZeneca (AZN), Eli Lilly and (LLY), Bristol-Myers Squibb (BMY), Celgene (CELG), Allergan (AGN), Zoetis (ZTS) and Vertex Pharmaceuticals (VRTX).

Who are Shire's key executives?

Shire's management team includes the folowing people:

Dr. Flemming Ornskov M.P.H., MBA, M.D., MPH, CEO, MD & Exec. Director (Age 60)
Mr. Thomas J. W. Dittrich, CFO & Director (Age 54)
Gisele Dion, Chief Accounting Officer
Mr. Matthew Walker, Head of Technical Operations (Age 54)
Prof. Andreas Busch Ph.D., Head of R&D & Chief Scientific Officer (Age 55)

Has Shire been receiving favorable news coverage?

News stories about SHPG stock have trended somewhat positive on Tuesday, Accern reports. Accern identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Shire earned a coverage optimism score of 0.03 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 48.37 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are Shire's major shareholders?

Shire's stock is owned by a variety of of retail and institutional investors. Top institutional investors include The Manufacturers Life Insurance Company (0.61%), Northern Trust Corp (0.34%), BlackRock Inc. (0.30%), Rockefeller Capital Management L.P. (0.25%), New South Capital Management Inc. (0.22%) and Delek Group Ltd. (0.08%). View Institutional Ownership Trends for Shire.

Which major investors are selling Shire stock?

SHPG stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Point72 Asset Management L.P., MD Sass Investors Services Inc., BlackRock Inc., Guggenheim Capital LLC, PNC Financial Services Group Inc., Van ECK Associates Corp and Eagle Global Advisors LLC. View Insider Buying and Selling for Shire.

Which major investors are buying Shire stock?

SHPG stock was bought by a variety of institutional investors in the last quarter, including Rockefeller Capital Management L.P., Prosight Management LP, Delek Group Ltd., Sphera Funds Management LTD., Dimensional Fund Advisors LP, First Light Asset Management LLC, Forsta AP Fonden and Sector Gamma AS. View Insider Buying and Selling for Shire.

How do I buy shares of Shire?

Shares of SHPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Shire's stock price today?

One share of SHPG stock can currently be purchased for approximately $169.89.

How big of a company is Shire?

Shire has a market capitalization of $51.55 billion and generates $15.16 billion in revenue each year. The biopharmaceutical company earns $4.27 billion in net income (profit) each year or $15.15 on an earnings per share basis. Shire employs 23,044 workers across the globe.

How can I contact Shire?

Shire's mailing address is BLOCK 2 MIESIAN PLAZA 50-58 BAGGOT STREET LOWER, Dublin L2, D02. The biopharmaceutical company can be reached via phone at 353-1609-6000 or via email at [email protected]

MarketBeat Community Rating for Shire (SHPG)

Community Ranking:		3.3 out of 5 ( )
Outperform Votes:		929 (Vote Outperform)
Underperform Votes:		463 (Vote Underperform)
Total Votes:		1,392

MarketBeat's community ratings are surveys of what our community members think about Shire and other stocks. Vote "Outperform" if you believe SHPG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SHPG will underperform the S&P 500 over the long term. You may vote once every thirty days.

Shire (NASDAQ:SHPG) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

17 Wall Street analysts have issued ratings and price targets for Shire in the last 12 months. Their average twelve-month price target is $201.6429, suggesting that the stock has a possible upside of 18.69%. The high price target for SHPG is $245.00 and the low price target for SHPG is $150.00. There are currently 5 hold ratings and 12 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.71	2.69	2.71	2.63
Ratings Breakdown:	0 Sell Rating(s) 5 Hold Rating(s) 12 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 5 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 5 Hold Rating(s) 12 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 6 Hold Rating(s) 10 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$201.6429	$205.00	$204.00	$212.1818
Price Target Upside:	18.69% upside	27.50% upside	61.05% upside	51.53% upside

Shire (NASDAQ:SHPG) Consensus Price Target History

Price Target History for Shire (NASDAQ:SHPG)

Shire (NASDAQ:SHPG) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/11/2018	Kepler Capital Markets	Reiterated Rating	Buy ➝ Buy		Low
5/8/2018	Royal Bank of Canada	Reiterated Rating	Buy		Low
4/29/2018	BTIG Research	Reiterated Rating	Buy	$195.00	Low
4/19/2018	B. Riley	Boost Price Target	Buy	$200.00	Low
4/16/2018	Cantor Fitzgerald	Set Price Target	Buy	$222.00	Medium
3/28/2018	Bank of America	Reiterated Rating	Buy		High
2/20/2018	SunTrust Banks	Lower Price Target	Buy	$190.00	Medium
2/20/2018	JPMorgan Chase	Reiterated Rating	Overweight ➝ Neutral		Medium
2/14/2018	Sanford C. Bernstein	Upgrade	Market Perform ➝ Outperform		Medium
1/5/2018	Cowen	Set Price Target	Buy	$225.00	Low
1/3/2018	Piper Jaffray Companies	Reiterated Rating	Hold		Low
12/20/2017	Liberum Capital	Reiterated Rating	Buy ➝ Hold		Medium
10/30/2017	FBR & Co	Reiterated Rating	Buy	$201.00	N/A
10/8/2017	Stifel Nicolaus	Reiterated Rating	Buy	$245.00	N/A
8/16/2017	Evercore ISI	Initiated Coverage	Outperform ➝ Outperform	$196.00	Medium
8/11/2017	Barclays	Downgrade	Overweight ➝ Equal Weight		Low
8/9/2017	Jefferies Group	Reiterated Rating	Hold	$216.00 ➝ $206.00	Low
4/17/2017	Goldman Sachs	Boost Price Target	Overweight	$202.00 ➝ $214.00	Low
2/17/2017	Guggenheim	Reiterated Rating	Neutral		N/A
12/6/2016	UBS	Downgrade	Buy ➝ Hold		N/A
12/2/2016	Societe Generale	Initiated Coverage	Buy		N/A
11/14/2016	Leerink Swann	Set Price Target	Buy	$198.00	N/A
11/3/2016	Citigroup	Reiterated Rating	Buy		N/A
11/2/2016	Deutsche Bank	Reiterated Rating	Buy		N/A
10/23/2016	BNP Paribas	Reiterated Rating	Buy		N/A
10/8/2016	Shore Capital	Reiterated Rating	Buy		N/A
6/3/2016	Morgan Stanley	Reiterated Rating	Overweight		N/A
5/23/2016	Bryan, Garnier & Co	Initiated Coverage	Buy		N/A

(Data available from 5/22/2016 forward)

Shire (NASDAQ:SHPG) Earnings History and Estimates Chart

Earnings by Quarter for Shire (NASDAQ:SHPG)

Shire (NASDAQ:SHPG) Earnings Estimates

2018 EPS Consensus Estimate: $15.38
2019 EPS Consensus Estimate: $15.58

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	5	$3.54	$4.01	$3.81
Q2 2018	6	$3.64	$3.97	$3.76
Q3 2018	6	$3.64	$4.08	$3.81
Q4 2018	6	$3.78	$4.37	$4.00
Q1 2019	2	$3.58	$3.93	$3.76
Q2 2019	2	$3.73	$3.99	$3.86
Q3 2019	2	$3.77	$3.95	$3.86
Q4 2019	2	$3.98	$4.23	$4.11

Shire (NASDAQ SHPG) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/2/2018
4/26/2018	3/31/2018	$3.58	$3.86		$3.7657 billion	View	N/A
2/14/2018	n/a	$3.86	$3.98		$4.1449 billion	View	N/A
10/27/2017	9/30/2017	$3.64	$3.81		$3.6976 billion	View	N/A
8/3/2017	6/30/2017	$3.53	$3.73		$3.7458 billion	View	Listen
5/2/2017	Q1 17	$3.22	$3.63		$3.5723 billion	View	Listen
2/16/2017	Q416	$3.24	$3.37	$3.7752 billion	$3.8061 billion	View	N/A
11/1/2016	Q316	$3.21	$3.17	$3.57 billion	$3.45 billion	View	N/A
8/2/2016	Q216	$3.03	$3.38	$2.2757 billion	$2.43 million	View	N/A
4/29/2016	Q1	$3.0540	$3.19	$1.71 billion	$1.71 billion	View	Listen
2/11/2016	Q415	$2.89	$2.97	$1.69 million	$1.7160 billion	View	Listen
10/23/2015	Q315	$2.87	$3.24	$1.63 billion	$1.58 billion	View	Listen
7/23/2015	Q215	$2.81	$2.63	$1.59 billion	$1.56 billion	View	Listen
4/30/2015	Q115	$2.56	$2.84	$1.47 billion	$1.49 billion	View	N/A
2/12/2015	Q115	$2.68	$2.63	$1.5293 billion	$1.5761 billion	View	N/A
10/24/2014	Q314	$2.47	$2.93	$1.46 billion	$1.55 billion	View	Listen
7/18/2014	Q214	$2.45	$2.67	$1.45 billion	$1.50 billion	View	N/A
5/1/2014	Q114	$2.22	$2.36	$1.38 billion	$1.35 billion	View	N/A
2/13/2014	Q413	$2.02	$2.26	$1.28 billion	$1.33 billion	View	N/A
10/24/2013	Q213	$1.65	$1.77	$1.23 billion	$1.24 billion	View	N/A
7/25/2013		$1.60	$1.79	$1.2146 billion	$1.2750 billion	View	N/A
5/2/2013	Q113	$1.56	$1.63	$1.21 billion	$1.16 billion	View	N/A
2/14/2013	Q412	$1.58	$1.58	$1.20 billion	$1.20 billion	View	N/A
10/25/2012		$1.47	$1.36			View	N/A
8/1/2012		$1.52	$1.68			View	N/A
4/26/2012		$0.52	$1.24			View	N/A
2/9/2012		$0.48	$0.44			View	N/A
10/28/2011		$1.31	$1.28			View	N/A
7/28/2011		$1.24	$1.33			View	N/A
4/28/2011		$1.18	$1.23			View	N/A
2/10/2011		$1.04	$1.03			View	N/A
10/29/2010	Q3 2010	$0.98	$1.16			View	N/A
8/4/2010	Q2 2010	$0.88	$1.03			View	N/A
4/29/2010	Q1 2010	$0.84	$1.01			View	N/A
2/19/2010	Q4 2009	$0.58	$1.10			View	N/A
10/30/2009	Q3 2009	$0.48	$0.49			View	N/A
8/5/2009	Q2 2009	$0.47	$0.60			View	N/A
4/30/2009	Q1 2009	$1.08	$1.28			View	N/A
2/19/2009	Q4 2008	$1.00	$1.01			View	N/A
10/29/2008	Q3 2008	$0.87	$1.17			View	N/A
7/31/2008	Q2 2008	$0.75	$0.95			View	N/A
4/25/2008	Q1 2008	$0.72	$0.74			View	N/A
2/21/2008	Q4 2007	$0.64	$0.94			View	N/A

(Earnings results data provided by Zacks Investment Research)

Shire (NASDAQ:SHPG) Dividend Information

Shire pays an annual dividend of $1.05 per share, with a dividend yield of 0.62%. SHPG's most recent semiannual dividend payment was Tuesday, April 24. Shire pays out 6.93% of its earnings out as a dividend.

Most Recent Dividend:	4/24/2018
Annual Dividend:	$1.05
Dividend Yield:	0.62%
Payout Ratio(s):	6.93% (Trailing 12 Months of Earnings) 6.88% (Based on This Year's Estimates) 6.48% (Based on Next Year's Estimates) 4.62% (Based on Cash Flow)

Dividend Payments by Quarter for Shire (NASDAQ:SHPG)

Shire (NASDAQ:SHPG) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/16/2018	semiannual	$0.8937	1.33%	3/8/2018	3/9/2018	4/24/2018
8/11/2017	semiannual	$0.1527	0.21%	9/7/2017	9/8/2017	10/20/2017
2/24/2017		$0.7710		3/8/2017	3/10/2017	4/25/2017
8/5/2016		$0.1390		9/7/2016	9/9/2016	10/7/2016
2/11/2016		$0.6650		3/9/2016	3/11/2016	4/12/2016
7/23/2015		$0.1263		9/2/2015	9/4/2015	10/2/2015
2/23/2015	semiannual	$0.5727	0.48%	3/11/2015	3/13/2015	4/14/2015
8/4/2014	semiannual	$0.1149	0.09%	9/3/2014	9/5/2014	10/3/2014
2/20/2014	semiannual	$0.5079	0.61%	3/5/2014	3/7/2014	4/8/2014
7/29/2013	semiannual	$0.09	0.16%	9/4/2013	9/6/2013	10/3/2013
2/19/2013	semiannual	$0.4380	0.92%	3/6/2013	3/8/2013	4/9/2013

(Data available from 1/1/2013 forward)

Shire (NASDAQ SHPG) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.00%
Institutional Ownership Percentage: 18.12%

Insider Trading History for Shire (NASDAQ:SHPG)

Institutional Ownership by Quarter for Shire (NASDAQ:SHPG)

Shire (NASDAQ SHPG) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details

(Data available from 1/1/2013 forward)

Shire (NASDAQ SHPG) News Headlines

Source:

Date	Headline
	SHIRE RELEASES DATA AT THE WFH CONGRESS 2018 EVALUATING VONVENDI® IN ADULTS WITH VON ... globenewswire.com - May 22 at 8:16 AM
	Shire (SHPG) Receives Average Rating of "Buy" from Analysts www.americanbankingnews.com - May 20 at 1:41 PM
	FOCUS-Takeda CEO prescribes surgical R&D cuts after $62 bln Shire deal finance.yahoo.com - May 17 at 8:17 AM
	Takeda CEO prescribes surgical R&D cuts after $62 billion Shire deal finance.yahoo.com - May 17 at 8:17 AM
	Shire plc: Rule 2.9 Announcement finance.yahoo.com - May 16 at 8:15 AM
	Shire Recognizes MPS Awareness Day 2018 with Digital Campaign and Global Events Focused on Increasing ... www.prnewswire.com - May 15 at 8:21 AM
	Shire Recognizes MPS Awareness Day 2018 with Digital Campaign and Global Events Focused on Increasing Diseases Awareness finance.yahoo.com - May 15 at 8:21 AM
	$3.81 Billion in Sales Expected for Shire (SHPG) This Quarter www.americanbankingnews.com - May 15 at 4:59 AM
	Takeda and Shire: A Pricey Marriage www.fool.com - May 14 at 6:35 PM
	Q2 2018 EPS Estimates for Shire Boosted by Analyst (SHPG) www.americanbankingnews.com - May 14 at 1:43 AM
	Shire (SHPG) Short Interest Up 110.7% in April www.americanbankingnews.com - May 13 at 1:40 AM
	Zacks: Brokerages Anticipate Shire (SHPG) to Post $3.69 EPS www.americanbankingnews.com - May 13 at 1:20 AM
	Shire (SHPG) Coverage Initiated by Analysts at Kepler Capital Markets www.americanbankingnews.com - May 11 at 9:19 PM
	Takeda Pharmaceutical's (TKPHF) CEO Christophe Weber on the Proposed Acquisition of Shire PLC Group (Transcript) seekingalpha.com - May 11 at 6:03 PM
	Whisky and Apologies Aided Takeda's $62 Billion Shire Gamble www.bloomberg.com - May 11 at 8:18 AM
	Iconic Genzyme building faces uncertain future after Shire-Takeda deal finance.yahoo.com - May 11 at 8:18 AM
	Takeda Shareholders Should Come Around to Shire finance.yahoo.com - May 10 at 8:19 AM
	Takeda Pharmaceutical Company Limited -- Moody's downgrades Takeda Pharmaceutical to A2; places ratings on review for further downgrade finance.yahoo.com - May 9 at 8:15 AM
	Takeda Near Deal to Buy Shire (SHPG) for $64 Billion - Bloomberg www.streetinsider.com - May 8 at 5:45 PM
	Royal Bank of Canada Reiterates Buy Rating for Shire (SHPG) www.americanbankingnews.com - May 8 at 10:22 AM
	Iran Day, Takeda and Shire, Athenahealth Bid: CEO Daily for May 8, 2018 fortune.com - May 8 at 8:12 AM
	Takeda Clinches $62 Billion Deal to Buy Drugmaker Shire www.bloomberg.com - May 8 at 8:12 AM
	Japan's Takeda agrees $62 billion takeover of Shire www.reuters.com - May 8 at 8:12 AM
	Shire rally pushes FTSE 100 to 14-week high www.marketwatch.com - May 8 at 8:12 AM
	Blog Exposure - FDA Granted Fast Track Designation for REGENXBIO's RGX-121 Gene Therapy for Mucopolysaccharidosis Type II finance.yahoo.com - May 4 at 8:15 AM
	Shire (SHPG) Rating Lowered to Sell at ValuEngine www.americanbankingnews.com - May 2 at 6:02 PM
	FY2018 EPS Estimates for Shire Lifted by Analyst (SHPG) www.americanbankingnews.com - May 2 at 9:26 AM
	Shire plc : Form 8 (DD) - Thomas Dittrich globenewswire.com - May 2 at 8:18 AM
	The Takeda-Shire Deal: Potential Impact On Neuroscience seekingalpha.com - May 1 at 8:19 AM
	Shire plc : Total voting rights finance.yahoo.com - May 1 at 8:19 AM
	Shire plc : Form 8 (DD) - Flemming Ornskov finance.yahoo.com - May 1 at 8:19 AM
	What Analysts Recommend for BioMarin Pharmaceutical in April 2018 finance.yahoo.com - April 30 at 8:18 AM
	Q2 2018 Earnings Estimate for Shire Issued By B. Riley (SHPG) www.americanbankingnews.com - April 30 at 1:28 AM
	Analysts Issue Forecasts for Shire's Q2 2018 Earnings (SHPG) www.americanbankingnews.com - April 30 at 1:25 AM
	Shire to Post Q2 2018 Earnings of $3.80 Per Share, Piper Jaffray Forecasts (SHPG) www.americanbankingnews.com - April 30 at 1:25 AM
	Shire's (SHPG) Buy Rating Reiterated at BTIG Research www.americanbankingnews.com - April 29 at 9:17 AM
	Once-bitten merger arbitrageurs are twice Shire www.nasdaq.com - April 27 at 8:26 AM
	Shire Sales Exceed Estimates, Potentially Calming Deal Concerns www.bloomberg.com - April 27 at 8:26 AM
	Shire: Were Earnings Good Enough To Warrant Takeover Talk? seekingalpha.com - April 27 at 8:26 AM
	Short Interest in Shire (SHPG) Declines By 69.4% www.americanbankingnews.com - April 27 at 3:42 AM
	Zacks: Analysts Expect Shire (SHPG) Will Announce Quarterly Sales of $3.78 Billion www.americanbankingnews.com - April 27 at 2:56 AM
	Shire (SHPG) Posts Quarterly Earnings Results, Beats Expectations By $0.28 EPS www.americanbankingnews.com - April 26 at 6:32 PM
	Shire (SHPG) Issues FY18 Earnings Guidance www.americanbankingnews.com - April 26 at 9:26 AM
	Shire profit rises on higher sales, backs outlook www.marketwatch.com - April 26 at 8:13 AM
	Bid target Shire grows earnings six percent, holds cautious outlook finance.yahoo.com - April 26 at 8:13 AM
	[$$] Shire Q1 sales rise 7% driven by immunology and new treatments finance.yahoo.com - April 26 at 8:13 AM
	Shire plc : 1st Quarter Results feeds.benzinga.com - April 26 at 7:57 AM
	Traders Buy High Volume of Shire Put Options (SHPG) www.americanbankingnews.com - April 26 at 6:34 AM
	Shire (SHPG) Receives Average Recommendation of "Buy" from Brokerages www.americanbankingnews.com - April 25 at 1:36 PM
	Shire (SHPG) Expected to Announce Earnings of $3.58 Per Share www.americanbankingnews.com - April 25 at 1:24 PM

Shire (NASDAQ:SHPG) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Shire (NASDAQ:SHPG) Income Statement, Balance Sheet and Cash Flow Statement

Shire (NASDAQ SHPG) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff